Last reviewed · How we verify
Morphine plus Nalbuphine
At a glance
| Generic name | Morphine plus Nalbuphine |
|---|---|
| Also known as | Infumorph and NALUFIN |
| Sponsor | Abdelrady S Ibrahim, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Integrated Artificial Intelligence Approach for Predicting Analgesic Time Based on Nalbuphine Versus Morphine as Adjuvants to Bupivacaine in Ultrasound-Guided Supraclavicular Block (PHASE4)
- Postoperative Pain Management of Caesarean Section
- Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia (PHASE3)
- Comparison of Morphine With Nalbuphine in a Multimodal Approach for Pain Relief in Patients Undergoing Gynecological Procedures: Randomized Controlled Double Blind Clinical Trial (NA)
- Effect of IV Nalbuphine on Nausea and Vomiting Following Intrathecal Morphine (NA)
- Nalbuphine Versus Morphine for Perioperative Tumor Ablation (PHASE4)
- Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal Surgery (PHASE3)
- Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine plus Nalbuphine CI brief — competitive landscape report
- Morphine plus Nalbuphine updates RSS · CI watch RSS
- Abdelrady S Ibrahim, MD portfolio CI